Trial · NCT03118739
Results by group168
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 168
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Urinary Albumin to Creatinine Ratio (UACR) | Verinurad 9 mg+Febuxostat 80 mg | -48.65 | 95% Confidence Interval -64.807 to -25.089 | Precent change | |
| Urinary Albumin to Creatinine Ratio (UACR) | Placebo | -15.31 | 95% Confidence Interval -43.244 to 26.370 | Precent change | |
| sUA | Verinurad 9 mg+Febuxostat 80 mg | 12 weeks | -56.81 | 95% Confidence Interval -63.879 to -48.350 | Percent change |
| sUA | Placebo | 12 weeks | 6.86 | 95% Confidence Interval -11.800 to 29.471 | Percent change |
| sUA | Verinurad 9 mg+Febuxostat 80 mg | 24 weeks | -61.93 | 95% Confidence Interval -68.274 to -54.319 | Percent change |
| sUA | Placebo | 24 weeks | 4.73 | 95% Confidence Interval -13.795 to 27.239 | Percent change |
| eGFR | Verinurad 9 mg+Febuxostat 80 mg | 12 weeks | 1.25 | 95% Confidence Interval -6.520 to 9.674 | Percent change |
| eGFR | Placebo | 12 weeks | -4.40 | 95% Confidence Interval -12.258 to 4.154 | Percent change |
| eGFR | Verinurad 9 mg+Febuxostat 80 mg | 24 weeks | -1.73 | 95% Confidence Interval -9.446 to 6.648 | Percent change |
| eGFR | Placebo | 24 weeks | 0.55 | 95% Confidence Interval -7.854 to 9.712 | Percent change |
| Serum Creatinine | Verinurad 9 mg+Febuxostat 80 mg | 12 weeks | -0.60 | 95% Confidence Interval -6.946 to 6.188 | Percent change |
| Serum Creatinine | Placebo | 12 weeks | 3.44 | 95% Confidence Interval -3.636 to 11.025 | Percent change |
| Serum Creatinine | Verinurad 9 mg+Febuxostat 80 mg | 24 weeks | 1.93 | 95% Confidence Interval -4.743 to 9.078 | Percent change |
| Serum Creatinine | Placebo | 24 weeks | 0.02 | 95% Confidence Interval -6.945 to 7.504 | Percent change |
| Serum Cystatin C | Verinurad 9 mg+Febuxostat 80 mg | 12 weeks | 3.252 | 95% Confidence Interval -1.3402 to 8.0581 | Percent change |
| Serum Cystatin C | Placebo | 12 weeks | 0.114 | 95% Confidence Interval -4.6520 to 5.1187 | Percent change |
| Serum Cystatin C | Verinurad 9 mg+Febuxostat 80 mg | 24 weeks | 5.412 | 95% Confidence Interval 0.5212 to 10.5418 | Percent change |
| Serum Cystatin C | Placebo | 24 weeks | 3.951 | 95% Confidence Interval -1.1612 to 9.3279 | Percent change |
| Serum High Sensitivity C-reactive Protein | Verinurad 9 mg+Febuxostat 80 mg | 12 weeks | 35.863 | 95% Confidence Interval 4.5883 to 76.4884 | Percent change |
| Serum High Sensitivity C-reactive Protein | Placebo | 12 weeks | 11.665 | 95% Confidence Interval -15.6408 to 47.8091 | Percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03118739/results